Transforming the Future of Medicine Using Single Cell Technologies
Single-cell technologies are revolutionizing biomedical research by allowing the investigation of individual cells and the molecular changes that lead to disease with unprecedented detail both in time and space. However, the translation of basic findings into the clinical routine for early diagnosis and personalized therapies poses many challenges. The MDC, Charité and BIH joined forces to establish the new Focus Area “Single Cell Approaches for Personalized Medicine” with the aim of translating single cell discoveries into clinical practice to improve diagnostics, early detection of disease and enable personalized treatments to reach the ultimate goal of increasing patients’ wellbeing.
Long-term corporations between scientists and clinical experts from multiple disciplines are required to successfully integrate single cell research and medical practice to improve healthcare. Four newly appointed junior groups are now closely collaborating with four leading clinicians to connect basic research with clinical practice. This bridge concept optimally combines the internationally leading position of the BIMSB-MDC in the development of single cell technologies with the clinical-translational potential of BIH/Charité. Moreover, a central bioportal and a clinical single cell sequencing (CSCS) pipeline are being established to streamline the process from sample collection to data analysis, to enable personalized and data driven treatment choices.
We are eager to present the projects and future directions of the Focus Area and the ground breaking potential of this collaborative effort.
We kindly invite you to join the Kick-Off Symposium for the MDC, Charité and BIH Focus Area “Single Cell Approaches for Personalized Medicine” held virtually on 20 May 2021, from 3 to 7 pm. Breakout rooms will allow participants to meet the speakers and interact.
We look forward to excellent talks, inspiring conversations and to welcoming you online!